Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, recently announced that MAM-06.301 has achieved preclinical proof-of-concept for the treatment of allergy and allergic asthma.

The compound, also referred to as beta-escin, was identified through screening as a potential anti-allergic compound. In the present study, MAM-06.301 was investigated in vivo in two mouse models for early and late-stage allergic reactions (passive cutaneous anaphylaxis and allergic asthma). In both models, beta-escin showed a potent dose-dependent inhibitory effect.

“Serious allergies can be extremely debilitating life-long problems, and there is evidence that their incidence is increasing,” said Dr. Andreas Grassauer, CEO and Co-Founder of Marinomed. “The current array of treatment options, such as steroids, antihistamines, and mast-cell stabilizers, suffer from issues of low patient compliance. We therefore hope that MAM-06.301 will be a safe alternative with high compliance in the future and plan to initiate a clinical trial in due course. ”

Marinomed Biotechnologie GmbH was founded in 2006 and develops therapies against respiratory diseases based on an innovative technology platform. The usability of this safe and effective technology has been proven by its first marketed product: an anti-viral nasal spray. The huge potential of the technology is reflected by Marinomed´s additional products concentrating on influenza, combination products for asthmatics, and other high-risk patients. In addition, the company develops a novel treatment against type I allergy and autoimmune diseases. Marinomed Biotechnologie GmbH is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria.